Figure 1 Characterization of... | American Society of Hematology

Figure 1

$Figure 1. Characterization of transplanted human fetal mesenchymal stem cells and experimental design. (A) Immunostaining for hematopoietic markers (CD14, CD34, and CD45), markers associated with pluripotency and telomerase activity (Nanog, Oct-4, and hTERT), MSC-associated markers (CD105, CD73, CD90, and STRO-1), adhesion molecules (CD44, CD29), and matrix proteins (vimentin and laminin). Original magnification, 40×/0.75 NA oil objective. (B) Cells were transplanted intraperitoneally in oim fetuses and analyzed 1, 2, 4, 8, and 12 weeks after birth. MSC indicates mesenchymal stem cells; A, bioluminescence; B, engraftment; C, fractures; D, 3-point bending; E, cortical thickness; F, bone length; and G, growth plate analysis.$

Characterization of transplanted human fetal mesenchymal stem cells and experimental design. (A) Immunostaining for hematopoietic markers (CD14, CD34, and CD45), markers associated with pluripotency and telomerase activity (Nanog, Oct-4, and hTERT), MSC-associated markers (CD105, CD73, CD90, and STRO-1), adhesion molecules (CD44, CD29), and matrix proteins (vimentin and laminin). Original magnification, 40×/0.75 NA oil objective. (B) Cells were transplanted intraperitoneally in oim fetuses and analyzed 1, 2, 4, 8, and 12 weeks after birth. MSC indicates mesenchymal stem cells; A, bioluminescence; B, engraftment; C, fractures; D, 3-point bending; E, cortical thickness; F, bone length; and G, growth plate analysis.

This Feature Is Available To Subscribers Only